Caliper's Q2 Revenues Fall, but Shares Rise as It Beats Expectations | GenomeWeb

NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported that its second-quarter revenues fell around 6 percent, but were up 8 percent on an organic basis, as the firm trimmed its net loss. It also beat analysts' consensus estimate for both revenues and net loss.

The Hopkinton, Mass.-based firm's stock was up 11 percent to $1.95 in early Thursday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.